OBJECTIVES: The aim of this study was to compare the in vivo activities of the new antistaphylococcal drugs ceftaroline fosamil, daptomycin and tigecycline at projected human therapeutic doses against methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant S. aureus (MRSA) and glycopeptide-intermediate S. aureus (GISA) strains in a rabbit model of endocarditis. METHODS: The efficacy of therapeutic regimens in our model was evaluated following 4 days of treatment by determining colony counts of infected vegetations. Emergence of resistant variants during therapy was assessed. RESULTS: Using this model of infective endocarditis, ceftaroline fosamil and daptomycin demonstrated high bactericidal in vivo activity (reduction of >5 log(10) cfu/g of vegetation) after a 4 day treatment against MSSA, MRSA and GISA strains. Both drugs were more efficacious than tigecycline, which showed moderate activity but failed to exhibit a bactericidal effect. Ceftaroline was superior to daptomycin in terms of sterilization of the vegetations. Emergence of resistant variants during daptomycin therapy was observed in two animals (one in the MSSA group and one in the MRSA group) but was not observed in ceftaroline- or tigecycline-treated animals. CONCLUSIONS: The novel β-lactam agent ceftaroline fosamil was the most active bactericidal drug in this model and is a promising therapeutic option for the treatment of severe S. aureus infections, including those caused by MRSA and GISA strains.
OBJECTIVES: The aim of this study was to compare the in vivo activities of the new antistaphylococcal drugs ceftaroline fosamil, daptomycin and tigecycline at projected human therapeutic doses against methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant S. aureus (MRSA) and glycopeptide-intermediate S. aureus (GISA) strains in a rabbit model of endocarditis. METHODS: The efficacy of therapeutic regimens in our model was evaluated following 4 days of treatment by determining colony counts of infected vegetations. Emergence of resistant variants during therapy was assessed. RESULTS: Using this model of infective endocarditis, ceftaroline fosamil and daptomycin demonstrated high bactericidal in vivo activity (reduction of >5 log(10) cfu/g of vegetation) after a 4 day treatment against MSSA, MRSA and GISA strains. Both drugs were more efficacious than tigecycline, which showed moderate activity but failed to exhibit a bactericidal effect. Ceftaroline was superior to daptomycin in terms of sterilization of the vegetations. Emergence of resistant variants during daptomycin therapy was observed in two animals (one in the MSSA group and one in the MRSA group) but was not observed in ceftaroline- or tigecycline-treated animals. CONCLUSIONS: The novel β-lactam agent ceftaroline fosamil was the most active bactericidal drug in this model and is a promising therapeutic option for the treatment of severe S. aureus infections, including those caused by MRSA and GISA strains.
Authors: Cristina El Haj; Oscar Murillo; Alba Ribera; Mireia Vivas; Dolors Garcia-Somoza; Fe Tubau; Javier Cabo; Javier Ariza Journal: Antimicrob Agents Chemother Date: 2014-06-23 Impact factor: 5.191
Authors: J M Entenza; T R Veloso; J Vouillamoz; M Giddey; P Majcherczyk; P Moreillon Journal: Antimicrob Agents Chemother Date: 2011-07-05 Impact factor: 5.191
Authors: P Tattevin; A Saleh-Mghir; B Davido; I Ghout; L Massias; C Garcia de la Maria; J M Miró; C Perronne; F Laurent; A C Crémieux Journal: Antimicrob Agents Chemother Date: 2012-12-17 Impact factor: 5.191
Authors: Warren E Rose; Lucas T Schulz; David Andes; Rob Striker; Andrew D Berti; Paul R Hutson; Sanjay K Shukla Journal: Antimicrob Agents Chemother Date: 2012-08-06 Impact factor: 5.191
Authors: A del Río; C García-de-la-Mària; J M Entenza; O Gasch; Y Armero; D Soy; C A Mestres; J M Pericás; C Falces; S Ninot; M Almela; C Cervera; J M Gatell; A Moreno; P Moreillon; F Marco; J M Miró Journal: Antimicrob Agents Chemother Date: 2015-11-02 Impact factor: 5.191